NeutralCGEMCullinan TherapeuticsCullinan TherapeuticsCLYMClimb BioClimb Bio
5/6/2026 on
Important biotech poll. $XBI $BBC $CGEM $CLYM #CD19 https://t.co/LBkBgNiNq6
View original →
Support https://t.co/TGSam331QD | Long-Term, Long-Only Biopharma Investor | Not financial or medical advice | COI = Likely invested in names I discuss
Cite asCryptoQuant has tracked 5 directional calls by @LuciusJameson on X since Feb 2025: tracked, not yet ranked (below the accuracy-scoring baseline) (as of Nov 11, 2026).
Important biotech poll. $XBI $BBC $CGEM $CLYM #CD19 https://t.co/LBkBgNiNq6
View original →Makary hasn’t yet called-out or conflated anything with $RCKT so we rally?
View original →The new consensus definition of long-term investing is now simply holding over night $XBI
View original →Most relevant $GMAB question: $XBI 1. Will >1 EGFR bsAb be commercially viable in HNSCC? 2. Did management consider full potential of drug Genmab created (Rybrevant) in HNSCC before acquiring $MRUS? 3. Is it too late to break-up with Merus & just go with 10% Rybrevant royalty?
View original →Early stage market rotation to healthcare ongoing $XBI
View original →